AtriCure Announces Launch Of cryoSPHERE MAX Probe For Post-Operative Pain Management

AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE MAX™cryoablation probe. The cryoSPHERE MAX probe features a larger ball tip designed to optimize Cryo Nerve Block™ therapy (cryoNB). The new probe reduces freeze times by 50% when compared to AtriCure's first generation cryoSPHERE® cryoablation probe, and over 30% when compared to the cryoSPHERE®+ probe.